Concord Wealth Partners Verona Pharma PLC Transaction History
Concord Wealth Partners
- $710 Million
- Q3 2025
A detailed history of Concord Wealth Partners transactions in Verona Pharma PLC stock. As of the latest transaction made, Concord Wealth Partners holds 7 shares of VRNA stock, worth $748. This represents 0.0% of its overall portfolio holdings.
Number of Shares
7
Previous 7
-0.0%
Holding current value
$748
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding VRNA
# of Institutions
274Shares Held
77.1MCall Options Held
686KPut Options Held
442K-
Pentwater Capital Management LP Naples, FL5.3MShares$567 Million3.55% of portfolio
-
Hbk Investments L P Dallas, TX4.26MShares$456 Million6.29% of portfolio
-
Fil LTD Hamilton, D03.49MShares$373 Million0.32% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA3.38MShares$362 Million15.27% of portfolio
-
Davidson Kempner Capital Management LP New York, NY3.27MShares$350 Million10.89% of portfolio
About Verona Pharma plc
- Ticker VRNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,954,200
- Market Cap $6.52B
- Description
- Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodi...